Humacyte Inc. Common Stock Q2 2025 Earnings Recap

Humacyte's second quarter 2025 results show significant growth following FDA approval of Symvess, evidenced by a surge in VAC approvals and expanded military sales, despite headwinds from recent CMS reimbursement challenges.

Key Takeaways

• Symvess commercial adoption accelerated, with 82 civilian hospitals now authorized to purchase, up from just 5.
• Recorded July product sales of approximately $0.3 million surpassed total sales for the first half of 2025.
• Secured ECAT approval from the U.S. Defense Logistics Agency, resulting in the first sale to a military facility and continued interest for additional contracts.
• CMS denied the NTAP application for Symvess, which Humacyte believes will have limited impact due to the small percentage of Medicare patients affected.
• ATEV Phase III trial results were well-received at a major medical conference, highlighting superior outcomes for patients at high risk of fistula nonmaturation.